Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | CDK3 | Q00526 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15077175 | 0.84 | CCNT1 (0.33) | CCNT1CDK1CDK4CCNA2CCND1 | |
| SCHEMBL20952890 | 0.77 | CYP17A1 (0.32) | — | |
| SCHEMBL24045536 | 0.74 | IRAK4 (0.31) | IRAK4CCNT1CDK1CDK4CCNA2 | |
| SCHEMBL18237744 | 0.72 | NOTUM (0.34) | — | |
| SCHEMBL25482782 | 0.69 | IRAK4 (0.45) | IRAK4 | |
| SCHEMBL17248121 | 0.69 | PDE10A (0.34) | — | |
| SCHEMBL6842146 | 0.69 | MKNK1 (0.49) | IRAK4CDK1CDK2 | |
| SCHEMBL22217009 | 0.69 | USP9X (0.33) | — | |
| SCHEMBL20696288 | 0.69 | — | — | |
| SCHEMBL20476168 | 0.68 | IRAK4 (0.32) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024092011-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-10787453-B2 | Octahydropyrrolopyrroles their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-09-29 | — | — | US | disclosed |
| US-10570148-B2 | N-alkyl-2-phenoxyethanamines, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-02-25 | — | — | US | disclosed |
| US-10421720-B2 | Octahydrocyclopentapyrroles, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-09-24 | — | — | US | disclosed |
| US-20190031681-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-01-31 | — | — | US | disclosed |
| US-20180222919-A1 | N-ALKYL-2-PHENOXYETHANAMINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-08-09 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-9637450-B2 | Octahydrocyclopentapyrroles, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637450-B2 | Octahydrocyclopentapyrroles, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-05-02 | — | — | US | disclosed |
| WO-2016183359-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| US-20160046632-A1 | OCTAHYDROPYRROLOPYRROLES THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046649-A1 | N-ALKYL-2-PHENOXYETHANAMINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160024007-A1 | OCTAHYDROCYCLOPENTAPYRROLES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-01-28 | — | — | US | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165472-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | IRAK4 101/4885CCNT1 4853/4885CDK1 4739/4885 |
| US-10570148-B2 | N-alkyl-2-phenoxyethanamines, their preparation and use | HRH3, CBR3, KCNH3 | IRAK4 4693/4885CCNT1 182/4885CDK1 777/4885 |
| US-20160046632-A1 | OCTAHYDROPYRROLOPYRROLES THEIR PREPARATION AND USE | QDPR, DPYD, DHPS | IRAK4 2044/4885CCNT1 2904/4885CDK1 2124/4885 |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | IRAK4 4611/4885CCNT1 2052/4885CDK1 1224/4885 |
| US-20130165472-A1 | HETEROARYLS AND USES THEREOF | PIK3R4, VPS4B, PIK3C2A | IRAK4 110/4885CCNT1 333/4885CDK1 526/4885 |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | PIK3R5, PIK3R4, PIK3C2B | IRAK4 485/4885CCNT1 932/4885CDK1 1824/4885 |
| US-11666594-B2 | Antibody-drug conjugates comprising a cyclic dinucleotide | STING1, TLR9, CGAS | IRAK4 101/4885CCNT1 4853/4885CDK1 4739/4885 |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885CCNT1 3525/4885CDK1 838/4885 |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | IRAK4 4611/4885CCNT1 2052/4885CDK1 1224/4885 |
| US-20160046649-A1 | N-ALKYL-2-PHENOXYETHANAMINES, THEIR PREPARATION AND USE | HRH3, CBR3, KCNH3 | IRAK4 4693/4885CCNT1 182/4885CDK1 777/4885 |
| US-20190031681-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | HTR3C, HRH4, CYP4F3 | IRAK4 2885/4885CCNT1 343/4885CDK1 412/4885 |
| US-10421720-B2 | Octahydrocyclopentapyrroles, their preparation and use | CLN6, ALDH1A2, C1S | IRAK4 4233/4885CCNT1 339/4885CDK1 1116/4885 |
| US-20180222919-A1 | N-ALKYL-2-PHENOXYETHANAMINES, THEIR PREPARATION AND USE | HRH3, CBR3, KCNH3 | IRAK4 4693/4885CCNT1 182/4885CDK1 777/4885 |
| US-20160024007-A1 | OCTAHYDROCYCLOPENTAPYRROLES, THEIR PREPARATION AND USE | CLN6, ALDH1A2, C1S | IRAK4 4233/4885CCNT1 339/4885CDK1 1116/4885 |
| US-10787453-B2 | Octahydropyrrolopyrroles their preparation and use | QDPR, DPYD, DHPS | IRAK4 2044/4885CCNT1 2904/4885CDK1 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.